DiseaseSignal
Breakthrough bottleneck

Can a biomarker remain useful when its population, assay, clinical task, or biological source changes?

A biomarker can discriminate within one study without explaining where its signal comes from or whether performance will survive a new cohort, assay, threshold, or intended use.

Human observationalStrengtheningTracked since Jul 21, 2026Updated Jul 23, 2026

Independent clinical and method-development studies increasingly separate predictive performance from biological interpretation and external portability.

Who encounters this friction
Biomarker developers, laboratory scientists, statisticians, and clinical-validation teams.
Evidence so far

A locked seven-protein plasma assay separated vasculitis remission in an independent cohort, while a separate tissue-inference framework showed how missing proteins and tissue attribution affect interpretation of biofluid proteomics.

Why it matters

Reliable discrimination and a plausible biological explanation are complementary. Confusing them can make a promising panel look more portable than the evidence supports.

Missing proof

Prospective replication, prespecified thresholds, calibration across laboratories and populations, comparison with simpler models, and evidence connecting measured proteins to their biological source.

Next decisive test

Run a prospective external validation with a locked assay, task, threshold, and analysis plan, then test whether tissue attribution and calibration remain stable across sites and patient groups.

Evidence movement

What changed

Newest evidence first. Labels describe the bottleneck, not treatment effectiveness.

  1. Strengthening

    Independent-cohort discrimination and tissue-aware interpretation supplied complementary evidence that portability and biological origin require separate validation.

    2 linked primary sources

  2. Emerging

    Heart-failure studies showed that protein panels changed with the clinical task, arguing against a single context-free signature.

    1 linked primary source

Evidence trail

Primary studies and briefings

3 primary sources. Every interpretation remains bounded by the linked evidence.

Proteins

Read the DiseaseSignal evidence briefing

  1. Proteomic plasma panel for vasculitis remission PMID 42481524 · DOI 10.1038/s41467-026-75755-6
  2. MLMarker tissue inference and biomarker discovery PMID 42343371 · DOI 10.1186/s13059-026-04125-8

Proteins

Read the DiseaseSignal evidence briefing

  1. Prognostic protein panels in community heart failure PMID 42335150 · DOI 10.1371/journal.pone.0350697
How to read evidence movement

EmergingA newly supported problem worth tracking.

StrengtheningAdditional evidence reinforces the bottleneck framing.

MixedEvidence supports some parts while important conflicts or limits remain.

UnchangedNew evidence does not materially change the open problem.

WeakenedNew evidence reduces confidence that this is the central bottleneck.

These labels track an unresolved research problem. They do not score a treatment or predict benefit for an individual.